A Phase 2 interventional study of Pemetrexed - Before Protocol Amendment and Pemetrexed - After Protocol Amendment in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 173rd largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 39th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 25 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 129th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 73 in phase 2, and was the 41st registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles. Pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action. Purpose of the trial is to monitor the blood values of these biomolecules at different time intervals, to optimize the synergism between pemetrexed and gemcitabine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemetrexed - Before Protocol Amendment
Drug: Pemetrexed - After Protocol Amendment
500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
Also known as: LY231514, Alimta
500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
Also known as: LY231514, Alimta
Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3
dCK and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Time frame: pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)
Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3
dCK (see Outcome #1)and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Time frame: pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)
Best Objective Tumor Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured response (every 14 days for 6 cycles)
| Milestone | Pemetrexed |
|---|---|
| Started | 19 |
| Completed | 6 |
| Not completed | 13 |
| Withdrew: Disease progression | 4 |
| Withdrew: Adverse event | 7 |
| Withdrew: Physician decision | 2 |
dCK and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
| mRNA relative values (ratio with GAPDH) | dCK - Cycle 1 | dCK - Cycle 2 | dCK - Cycle 3 |
|---|---|---|---|
| Pre-Dose | 0.92 ± 0.03 | 0.92 ± 0.03 | 0.92 ± 0.02 |
| 1 Hour Post-Dose | 0.96 ± 0.04 | 0.95 ± 0.03 | 0.96 ± 0.03 |
| 2 Hours Post-Dose | 0.96 ± 0.04 | 0.96 ± 0.04 | 0.97 ± 0.02 |
| 4 Hours Post-Dose | 0.93 ± 0.04 | 0.94 ± 0.04 | 0.92 ± 0.03 |
| 6 Hours Post-Dose | 0.92 ± 0.03 | 0.91 ± 0.04 | 0.91 ± 0.03 |
| 24 Hours Post-Dose | 0.96 ± 0.04 | 0.97 ± 0.03 | 0.96 ± 0.03 |
| 48 Hours Post-Dose | 0.97 ± 0.04 | 0.96 ± 0.04 | 0.97 ± 0.03 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | Pemetrexed - Before Amendment | Pemetrexed - After Amendment |
|---|---|---|
| Partial Response | 1 | 0 |
| Stable Disease | 2 | 4 |
| Progressive Disease | 3 | 0 |
| Early Death | 1 | 0 |
| Unconfirmed Stable Disease | 5 | 3 |
dCK (see Outcome #1)and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
| mRNA relative values (ratio with GAPDH) | hENT - Cycle 1 | hENT - Cycle 2 | hENT - Cycle 3 |
|---|---|---|---|
| Pre-Dose | 0.86 ± 0.03 | 0.86 ± 0.03 | 0.87 ± 0.02 |
| 1 Hour Post-Dose | 0.88 ± 0.04 | 0.89 ± 0.04 | 0.90 ± 0.03 |
| 2 Hours Post-Dose | 0.88 ± 0.04 | 0.90 ± 0.04 | 0.90 ± 0.04 |
| 4 Hours Post-Dose | 0.86 ± 0.04 | 0.88 ± 0.05 | 0.86 ± 0.03 |
| 6 Hours Post-Dose | 0.86 ± 0.04 | 0.86 ± 0.04 | 0.86 ± 0.02 |
| 24 Hours Post-Dose | 0.89 ± 0.04 | 0.91 ± 0.04 | 0.91 ± 0.02 |
| 48 Hours Post-Dose | 0.90 ± 0.04 | 0.91 ± 0.04 | 0.91 ± 0.02 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 5/19 (26.3%) | 19/19 (100%) |
| Event | Pemetrexed |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/19 |
| Cardiac arrestCardiac disorders | 1/19 |
| Disease progressionGeneral disorders | 1/19 |
| Renal colicRenal and urinary disorders | 1/19 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/19 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/19 |
| HaemorrhageVascular disorders | 1/19 |
| Event | Pemetrexed |
|---|---|
| PyrexiaGeneral disorders | 14/19 |
| AstheniaGeneral disorders | 9/19 |
| Mucosal inflammationGeneral disorders | 8/19 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/19 |
| ConjunctivitisEye disorders | 6/19 |
| ConstipationGastrointestinal disorders | 6/19 |
| AnaemiaBlood and lymphatic system disorders | 5/19 |
| DiarrhoeaGastrointestinal disorders | 5/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/19 |
| FatigueGeneral disorders | 4/19 |
| Age Continuous(years) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| Mean | 69.1 ± 10.34 | 69.4 ± 6.45 | 69.2 ± 8.90 |
| Sex: Female, Male(Participants) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| Female | 3 | 5 | 8 |
| Male | 9 | 2 | 11 |
| Region of Enrollment(participants) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| Italy | 12 | 7 | 19 |
| Disease Stages(participants) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| Not Known | 0 | 1 | 1 |
| Stage IA | 2 | 0 | 2 |
| Stage IB | 1 | 0 | 1 |
| Stage IIA | 1 | 0 | 1 |
| Stage IIB | 0 | 1 | 1 |
| Stage IIIA | 0 | 1 | 1 |
| Stage IIIB | 3 | 2 | 5 |
| Stage IV | 5 | 2 | 7 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| 0 - Fully Active | 4 | 1 | 5 |
| 1 - Ambulatory, Restricted Strenuous Activity | 6 | 5 | 11 |
| 2 - Ambulatory, No Work Activities | 2 | 1 | 3 |
| Histopathological Grade(participants) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| Not Done | 7 | 2 | 9 |
| G1 - Well-Differentiated | 1 | 1 | 2 |
| G2 - Moderately Differentiated | 2 | 1 | 3 |
| G3 - Poorly Differentiated | 2 | 3 | 5 |
| Previous Anti-Tumor Treatment(participants) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| No | 5 | 1 | 6 |
| Yes | 7 | 6 | 13 |
| Previous Surgery(participants) | Pemetrexed - Before Amendment | Pemetrexed - After Amendment | Total |
|---|---|---|---|
| Surgery - No | 4 | 1 | 5 |
| Surgery - Yes: Pneumonectomy | 0 | 1 | 1 |
| Surgery - Yes: Lobectomy | 3 | 3 | 6 |
| Surgery - Yes: Other | 5 | 3 | 8 |
| Surgery - Yes: Radical | 5 | 4 | 9 |
8 further baseline measures are reported on the registry.
The record gives a start of Sep 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →